Home LiteratureArticle Details
PMID: 7799013 Published · ppublish English Clinical Trial Comparative Study Journal Article Randomized Controlled Trial

Gonadal function following chemotherapy for Hodgkin's disease: a comparative study of MVPP and a seven-drug hybrid regimen.

Clark ST, Radford JA, Crowther D, Swindell R, Shalet SM

Abstract

Gonadal function was assessed in 89 patients after chemotherapy for Hodgkin's disease (HD). Thirty-seven patients had received mechlorethamine, vinblastine, prednisolone, and procarbazine (MVPP) and 52 patients, a hybrid combination of chlorambucil, vinblastine, prednisolone, procarbazine, doxorubicin, vincristine, and etoposide (ChIVPP/EVA). Fifty men (MVPP, n = 21; ChIVPP/EVA, n = 29) with a median age of 26 years (range, 16 to 54) and 39 women (MVPP, n = 16; ChIVPP/EVA, n = 23) with a median age of 30 years (range, 15 to 47) were studied at a median of 30 months (range, 4 to 83) following chemotherapy. Semen analysis showed azoospermia in 35 of 37 men, and increased serum follicle-stimulating hormone (FSH) levels in this group confirmed severe germinal epithelial damage. Analysis of pretreatment semen in 28 men showed azoospermia in one, oligospermia in four (sperm count < 20 x 10(6)/mL), and a normal sperm count in the remaining 23. In the women, 26 of 34 (76%) with a regular menstrual cycle before commencing chemotherapy became amenorrheic following treatment. Menses returned in 10 women, who had a median age of 25 years (range, 21 to 34), and there were two pregnancies in this group. In the other 16, with a median age of 36 years (range, 27 to 47), amenorrhea persisted and premature ovarian failure was confirmed by increased serum gonadotrophins and reduced estradiol (E2) concentrations. Of the original eight women in whom menses were maintained following treatment, two subsequently developed amenorrhea and the clinical and biochemical features of an early menopause. In total, 18 of 34 women (53%) required hormone replacement therapy for chemotherapy-induced ovarian failure. There was no statistically significant difference in the frequency or severity of gonadal dysfunction between MVPP- and ChIVPP/EVA-treated patients. We conclude that both of these chemotherapy schedules cause substantial damage to gonadal function in both sexes.

MeSH Terms
Adolescent Adult Amenorrhea/chemically induced Antineoplastic Combined Chemotherapy Protocols/adverse effects Chlorambucil/adverse effects Doxorubicin/adverse effects Etoposide/adverse effects Female Follicle Stimulating Hormone/blood Hodgkin Disease/blood,drug therapy Humans Libido/drug effects Luteinizing Hormone/blood Male Mechlorethamine/adverse effects Menstrual Cycle/drug effects Middle Aged Prednisolone/adverse effects Primary Ovarian Insufficiency/chemically induced Procarbazine/adverse effects Prospective Studies Semen/drug effects Sex Hormone-Binding Globulin/analysis Sperm Count/drug effects Testis/drug effects,pathology Testosterone/blood Vinblastine/adverse effects Vincristine/adverse effects
Chemicals
Sex Hormone-Binding Globulin Chlorambucil Procarbazine Testosterone Mechlorethamine Vincristine Vinblastine Etoposide Doxorubicin Luteinizing Hormone Follicle Stimulating Hormone Prednisolone
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Clark S T
Department of Endocrinology, Christie Hospital National Health Service Trust, Manchester, United Kingdom.
Radford J A
Crowther D
Swindell R
Shalet S M
Supplementary Concepts
MVPP protocol (Protocol)
Article Info
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Abbr.
J Clin Oncol
ISSN
0732-183X
Published
1995-01-00
Pages
134-9
Language
English
Region
United States
NLM ID
8309333
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]